MAPT and Alzheimer disease: 18F-AV1451 can reflect advanced tau pathology in AD and is more relevant to dynamic clinical changes [153], but it failed to detect early pathology formation as CSF p-tau does [154], and didn’t reliably predict tau pathology in non-AD patients [154], suggesting its use mainly in the neuropathological diagnosis of AD [155].